Data Presented At Two Global Medical Congresses Reinforce Benefit Of Enbrel® (etanercept) For Patients With Chronic Inflammatory Conditions
Links shared publicly online about this topic.
- 254total visits
Data Presented At Two Global Medical Congresses Reinforce Benefit Of Enbrel® (etanercept) For Patients With Chronic Inflammatory Conditions
Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL,
View full resource at medicalnewstoday.com
Tags: Rheumatoid Arthritis Medication, Enbrel, Pfizer, Amgen, Safety, Medical
Most Recently Shared on May 31, 2011 at 8:06 am By:
Data Presented At Two Global Medical Congresses Reinforce Benefit Of Enbrel® (etanercept) For Patients With Chroni... http://mnt.to/3WwT
Also Shared By:
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel (etanercept) for Patients with Chronic Inflammatory Conditions - Drugs.com MedNews
drugs.com — “New Interim Results from the PRESERVE Study Evaluate ENBREL Therapy in Patients with Moderately Active Rheumatoid Arthritis Analysis of Ankylosing Spondylitis T” View full resource at drugs.com
Most Recently Shared on May 25, 2011 at 4:11 pm By:
Drugs and Devices OW OW Health
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel (etanercept) for Patients with... http://bit.ly/iNifhs #drug
Advertisement
MNT Bones/Orthopedic
@mnt_bones
Data Presented At Two Global Medical Congresses Reinforce Benefit Of Enbrel® (etanercept) For Patients With Chroni... http://mnt.to/3WwT
1 year ago...